Drug Profile
Research programme: cannabinoid receptor CB2 agonists - Boehringer Ingelheim
Latest Information Update: 16 Oct 2012
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Small molecules
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 16 Oct 2012 No development reported - Preclinical for Inflammation in USA (PO)
- 16 Oct 2012 No development reported - Preclinical for Pain in USA (PO)
- 10 Apr 2008 Preclinical trials in Inflammation in USA (PO)